Ching-Yi Chen

Ching-Yi Chen

Auto-generated profile, based on publicly available information

Ching-Yi Chen

Massey Cancer Center, Virginia Commonwealth University, Richmond, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
CCChing-Yi Chen
Ching-Yi Chen
PWPei-Ying Wu
Pei-Ying Wu
MSMichelle Van Scoyk
Michelle Van Scoyk
SSStephanie A. Simko
Stephanie A. Simko
CCChu-Fang Chou
Chu-Fang Chou
RWRobert A. Winn
Robert A. Winn
Lung cancer continues to be the leading cause of cancer death in the United States. Despite recent advances, the five-year survival rate for lung cancer compared to other cancers still remains fairly low. The discovery of molecular targets for lung cancer is key to the development of new approaches and therapies. Electrically silent voltage-gated potassium channel (KvS) subfamilies, which are unable to form functional homotetramers, are implicated in cell-cycle progression, cell proliferation and tumorigenesis. Here, we analyzed the expression of KvS subfamilies in human lung tumors and identified that potassium voltage-gated channel subfamily F member 1 (KCNF1) was up-regulated in non-small cell lung cancer (NSCLC). Silencing of KCNF1 in NSCLC cell lines reduced cell proliferation and tumor progression in mouse xenografts, re-established the integrity of the basement membrane, and enhanced cisplatin sensitivity. KCNF1 was predominately localized in the nucleoplasm and likely mediated its functions in an ion-independent manner. We identified integrin β4 subunit (ITGB4) as a downstream target for KCNF1. Our findings suggest that KCNF1 promotes lung cancer by enhancing ITGB4 signaling and implicate KCNF1 as a novel therapeutic target for lung cancer.